GNC 049
Alternative Names: GNC-049Latest Information Update: 25 Sep 2024
At a glance
- Originator Sichuan Baili Pharmaceutical
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Sep 2024 Preclinical development in Solid tumours is ongoing China (Sichuan Biokin Pharmaceuticals pipeline, September 2024)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
- 30 Mar 2020 Preclinical trials in Solid tumours in China (Parenteral) before March 2020 (Sichuan Baili Pharmaceutical pipeline March 2020 )